Adaptimmune Reports First Quarter Financial Results and Business Update
09 mai 2022 07h30 HE
|
Adaptimmune Therapeutics plc
- Pooled data from Cohort 1 of the SPEARHEAD-1 trial and the Phase 1 trial of afami-cel in patients with sarcoma to be presented as a poster at ASCO - - Preclinical data for two novel next-generation...
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
04 mai 2022 08h00 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 04, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment...
Adaptimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update
14 mars 2022 08h00 HE
|
Adaptimmune Therapeutics plc
- SPEARHEAD-1 met its primary endpoint - planning for afami-cel BLA submission in Q4 2022 for people with synovial sarcoma - - Moving to late-phase development with ADP-A2M4CD8: SURPASS-2 initiated...
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
26 janv. 2022 08h00 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the...
Translational Data at SITC 2021 from Adaptimmune’s Phase 1 SURPASS Trial Indicate Adding AKTi to Manufacturing May Contribute to Sustained Antitumor Activity of Next-gen SPEAR T-cells
12 nov. 2021 07h00 HE
|
Adaptimmune Therapeutics plc
- Inhibition of AKT signaling during ex vivo T-cell expansion phase of manufacturing provides further proliferative potential and enhanced memory phenotype of next-gen SPEAR T-cells - - Data suggests...
Adaptimmune to Present Data Updates at Upcoming CTOS and SITC Meetings
05 oct. 2021 08h00 HE
|
Adaptimmune Therapeutics plc
- Clinical update and translational data from SPEARHEAD-1 in patients with synovial sarcoma and MRCLS to be presented at CTOS - - The Company will host its first virtual medical symposium at CTOS - ...
Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial
13 sept. 2021 07h00 HE
|
Adaptimmune Therapeutics plc
- Confirmed complete response in ovarian cancer, and confirmed partial responses in ovarian, head and neck, esophagogastric junction, bladder, and synovial sarcoma cancers - - Majority of patients...
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
19 mai 2021 17h00 HE
|
Adaptimmune Therapeutics plc
- Data will support BLA filing for afamitresgene autoleucel next year - - Responses observed across a broad range of antigen expression - - Initial safety and durability are encouraging - ...
First Preclinical Data from Adaptimmune’s Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model
11 mai 2021 08h00 HE
|
Adaptimmune Therapeutics plc
- Preclinical data validate that human T-cells expressing a TCR targeting mesothelin, independent of HLA recognition, can kill human tumor cells - - HiT works as well, or better than, a TRuC...
Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT
27 avr. 2021 16h30 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 27, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial preclinical...